{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-109016","form_type":"8-K","ticker":"APM","cik":"0001734005","company_name":"Aptorum Group Ltd","filed_at":"2026-10-13T20:00:30+00:00","discovered_at":"2026-10-13T20:01:00.290982+00:00","generated_at":"2026-10-13T20:01:07.543301+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Niki BioSolutions names Thomas Freeburg CFO with $250K salary, 50,000 options at $8.83","bullets":["Board appointed Thomas Freeburg, 59, as CFO on Oct 9, 2026; two-year term commencing Sept 1, 2026, reporting to CEO Ian Huen.","Base salary $250,000, with $25,000 deferred until the company raises $3M cumulatively; rises to $275,000 at $5M raised; bonus up to 50% of salary.","Receives 50,000 stock options at an $8.83 exercise price under the Niki BioSolutions 2026 Equity Incentive Plan; 20 days PTO and $150/month tech allowance.","Qualifying termination severance: lump sum of remaining base salary through end of Initial Term or six months, whichever is greater, plus COBRA and full unvested equity acceleration.","Freeburg was CFO/Secretary/Treasurer of Interpace Biosciences (IDXG) from Feb 2021 to Mar 2023, with earlier SEC reporting roles at Tapestry (TPR) and Scholastic (SCHL)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-109016","json":"https://secwatch.observer/filing/0001213900-26-109016.json","markdown":"https://secwatch.observer/filing/0001213900-26-109016.md","text":"https://secwatch.observer/filing/0001213900-26-109016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1734005/000121390026109016/0001213900-26-109016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1734005/000121390026109016/ea0308307-8k_niki.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-13T20:01:07.543301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ebbc384223","claim":"Thomas Freeburg was appointed as Chief Financial Officer at Aptorum Group Ltd.","evidence_excerpt":"On October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”), appointed Thomas Freeburg as the Chief Financial Officer, to serve at the discretion of the Board, for a period of two years, commencing as of September 1, 2026, unless terminated sooner by either party.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1734005/000121390026109016/0001213900-26-109016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}